Skip to content
Artwork for The Seed Investor Daily Brief
The Seed Investor Daily Brief · Feb 14, 2025 · 5 min

Totem, Aracor AI, and Mair Therapeutics: Key Pre-Seed Funding Developments

In this episode of The Seed Investor Daily Brief, Michelle kicks off with an overview of the latest top Seed funding stories. The episode highlights Totem's successful $1.3 million pre-seed round, emphasizing their innovative Compass device. Aracor AI's impressive $4.5 million pre-seed funding is discussed, shedding light on their growth strategy and potential market impact. Mair Therapeutics is also featured, with insights into their focus and future plans within the healthcare sector. The episode concludes with closing remarks and a reminder for listeners to follow the podcast for ongoing updates on seed funding and emerging startup trends. (0:00) Welcome and top Seed funding stories (0:23) Totem's $1.3 million Pre-Seed round and Compass device (2:20) Aracor AI's $4.5 million Pre-Seed funding and growth strategy (4:13) Mair Therapeutics' focus and future plans (5:21) Closing remarks and follow us reminder

0:00-5:42

transcript

No transcript — this publisher did not publish one.

show notes

In this episode of The Seed Investor Daily Brief, Michelle kicks off with an overview of the latest top Seed funding stories. The episode highlights Totem's successful $1.3 million pre-seed round, emphasizing their innovative Compass device. Aracor AI's impressive $4.5 million pre-seed funding is discussed, shedding light on their growth strategy and potential market impact. Mair Therapeutics is also featured, with insights into their focus and future plans within the healthcare sector. The episode concludes with closing remarks and a reminder for listeners to follow the podcast for ongoing updates on seed funding and emerging startup trends.

(0:00) Welcome and top Seed funding stories
(0:23) Totem's $1.3 million Pre-Seed round and Compass device
(2:20) Aracor AI's $4.5 million Pre-Seed funding and growth strategy
(4:13) Mair Therapeutics' focus and future plans
(5:21) Closing remarks and follow us reminder